Sign inJoin waitlistJoin the waitlist

Andrew Birkeland

Associate Professor · University of California Davis Health

Credentials: · · · ·

History

University of California Davis Health
Present

Stanford University
2018–2019
University of Michigan
2014–2016
Otolaryngology – Head and Neck Surgery
University of Michigan
2012–2013
Weill Cornell Medicine
2008–2012
Columbia University
2010–2011

Research

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Journal of the National Comprehensive Cancer Network · 2022 · 456 citations
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Journal of the National Comprehensive Cancer Network · 2025 · 159 citations
Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice
Journal of Clinical Investigation · 2010 · 129 citations

MS
Matthew Spector
36 papers
Arnaud Bewley
23 papers
Marianne Abouyared
23 papers · 1 as a fellow
Andrew Shuman
22 papers
AR
Andrew Rosko
21 papers · 12 as a resident
Mark Prince
21 papers
Carol Bradford
20 papers
Jonathan McHugh
20 papers
PS
Paul Swiecicki
15 papers · 3 as a fellow
SC
Steven Chinn
15 papers
Gregory Farwell
14 papers
GW
Gregory Wolf
13 papers

Grants

UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program
National Cancer Institute · K12
PI · $810K · University of California at Davis
2011–2027
Fluorescence Lifetime Imaging/Spectroscopy System For Robotic Cancer Surgery Guidance
National Cancer Institute · R01
PI · $2.5M · University of California at Davis
2014–2027

Clinical trials

Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
Principal investigator · Withdrawn · Phase 2
University of California, Davis
2025–2026
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2026–2033
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Site PI · Recruiting · Phase 1
Bicara Therapeutics
2020–2027